MMAE-Based LIV1 ADC Achieves Sustained Tumor Control in Prostate Cancer Models

LIV1, a zinc transporter protein, sits on the surface of 72% of prostate tumors with minimal expression in healthy tissues. This makes it an ideal target for antibody-drug conjugates, a therapeutic class combining antibody specificity with potent cytotoxic payloads. Researchers developed 48D6, a humanized anti-LIV1 monoclonal antibody with substantially improved pharmacokinetics compared to previous versions. In mouse models, 48D6 achieved a half-life of 13.8 to 15.6 days, roughly 8-fold longer than earlier anti-LIV1 antibodies. For patients, this means less frequent dosing, potentially moving from twice-weekly to weekly or biweekly schedules while maintaining higher and more sustained tumor exposure.

What makes this study particularly interesting for prostate cancer is the discovery that different ADC payloads perform differently in prostate tumors. The initial ADC-2, using a Topo I inhibitor, worked well in breast and lung models but failed to inhibit prostate tumor growth significantly. Researchers then developed ADC-3 using MMAE, a microtubule-targeting agent. ADC-3 achieved substantial tumor suppression in prostate models, with one high-expressing tumor showing over 70 days of sustained control even after treatment stopped on day 28. This payload sensitivity appears specific to prostate biology and suggests that optimizing treatment specifically for prostate tumors could be critical for clinical success.

Combining LIV1 ADCs with PD-1 checkpoint inhibitors significantly outperformed single agents in models expressing both targets. This aligns with current treatment strategies and suggests synergistic benefits from combining targeted cytotoxicity with immune activation. Safety studies showed ADC-2 was well tolerated at all doses tested, with only minor and reversible lesions at the highest doses.

These results support progression to human trials, particularly in castration-resistant disease where new targets beyond androgen receptor pathways are desperately needed. The durability of response seen in preclinical models is noteworthy. If translatable to patients, this could enable more intermittent dosing and potentially offer sustained disease control.

Source.